Merz Group Joins the “Made for Germany” Initiative
Merz Group Participates in the “Made for Germany” Initiative The Merz Group has taken a significant step in reinforcing its commitment to Germany’s industrial and economic future by joining the…
Read MoreMerz Group Joins the “Made for Germany” Initiative
AbbVie Chooses North Carolina as Site for $1.4 Billion Manufacturing Campus
AbbVie Chooses North Carolina as Site for $1.4 Billion Advanced Manufacturing Facility AbbVie has unveiled an ambitious new chapter in its long-term growth strategy with the announcement of a $1.4…
IMAAVY® (nipocalimab-aahu) Demonstrates Sustained Disease Control Beyond Two Years Across a Broad gMG Patient Population
IMAAVY® (nipocalimab-aahu) Demonstrates Durable, Over Two-Year Disease Control Across a Broad gMG Patient Population Johnson & Johnson has unveiled new clinical findings highlighting the long-term efficacy and safety of IMAAVY®…
Late-Breaking PRESERVE Trial Data Assess XVIVO’s HOPE Preservation Strategy in Heart Transplantation
Late-Breaking PRESERVE Trial Findings Assess XVIVO’s HOPE Preservation Strategy in Heart Transplantation XVIVO, a global medical technology company specializing in organ preservation and transplantation, has announced encouraging late-breaking preliminary results…
Kennel Connection Forms Exclusive Diagnostic Partnership with Petwealth to Expand Clinical-Grade Pet Health Screening Nationwide
Kennel Connection Forms Exclusive Partnership with Petwealth to Deliver Clinical-Grade Pet Health Screening Across Pet Care Facilities Nationwide Kennel Connection, a leading provider of pet care facility management software and…
Kallyope Presents Phase 2b Data on Elismetrep, a Novel Migraine Therapy, at the American Academy of Neurology Annual Meeting
Kallyope Presents Phase 2b Data on Elismetrep, a Novel Migraine Therapy, at the American Academy of Neurology Annual Meeting Kallyope, a late-stage biopharmaceutical company focused on developing innovative treatments for…
Segal Trials Positioned to Support Next Wave of Clinical Development as Federal Fast-Tracking Boosts Psychedelic Therapies
As Federal Fast-Tracking of Psychedelic Treatments Gains Momentum, Segal Trials Is Poised to Advance the Next Stage of Clinical Development The recent federal directive encouraging the U.S. Food and Drug…
OrganaBio and RxMP Therapeutics Forge Manufacturing Partnership to Advance RMP-402 Hemostatic Therapy
OrganaBio and RxMP Therapeutics Forge Manufacturing Alliance to Advance Development of RMP-402 Hemostatic Therapy OrganaBio and RxMP Therapeutics have announced a strategic manufacturing partnership aimed at advancing the development of…
Flatiron Health Highlights 18 Accepted Studies Leveraging Real-World Data for Presentation at ISPOR 2026
Flatiron Health Highlights 18 Accepted Studies Leveraging Real-World Data for Presentation at ISPOR 2026 Flatiron Health has announced a significant presence at the ISPOR Annual Meeting 2026, taking place from…
Vistagen Clears FDA Review to Advance Refisolone Phase 2 for Menopause Hot Flashes
Vistagen Secures FDA “Study May Proceed” Clearance for Refisolone IND, Advancing Phase 2 Development in Menopause-Related Vasomotor Symptoms Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company focused on advancing neuroscience…
Shields Health Solutions Collaborates with Columbus Regional Health to Expand Access to Specialty Pharmacy Services
Shields Health Solutions Collaborates with Columbus Regional Health to Expand Access to Specialty Pharmacy Care Shields Health Solutions, a leading specialty pharmacy integrator and accelerator in the United States, has…
Vyome Showcases Breakthrough Phase 2 Data for VT-1953 at AACR 2026
Vyome Showcases Transformative Phase 2 Clinical Results for VT-1953 at AACR 2026 Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage biotechnology company focused on developing innovative therapies for underserved conditions, has…